Fulcrum Therapeutics Files 8-K

TL;DR

Fulcrum Therapeutics filed an 8-K on 9/24/24 for exit/disposal costs and financials.

AI Summary

Fulcrum Therapeutics, Inc. filed an 8-K on September 24, 2024, to report on cost associated with exit or disposal activities and financial statements and exhibits. The filing does not contain specific dollar amounts or details regarding the nature of these activities.

Why It Matters

This filing indicates potential restructuring or divestiture activities within Fulcrum Therapeutics, which could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities' without providing specifics, suggesting potential operational changes or financial restructuring that could carry risks.

Key Players & Entities

• Fulcrum Therapeutics, Inc. (company) — Registrant
• September 24, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share FULC Nasdaq Global Market
• $2.0 million — o incur one-time costs of approximately $2.0 million in connection with this workforce reduc
• $10.0 million — rating expense savings of approximately $10.0 million beginning in the first quarter of 2025.

Filing Documents

• fulc-20240924.htm (8-K) — 51KB
• 0000950170-24-109069.txt ( ) — 172KB
• fulc-20240924.xsd (EX-101.SCH) — 30KB
• fulc-20240924_htm.xml (XML) — 5KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 24, 2024, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and its early discovery programs. The plan will reduce the Company's workforce from 80 to 51 full-time employees, including a reduction of positions across both research and development and general and administrative. Fulcrum expects to incur one-time costs of approximately $2.0 million in connection with this workforce reduction, primarily related to cash payments for severance. The Company communicated the workforce reduction on September 24, 2024, and expects the majority of the costs associated with the reduction to be incurred during the third quarter ending September 30, 2024. The Company expects that the implementation of the workforce reduction will be substantially complete by the end of the third quarter of 2024. The workforce reduction is expected to result in annual operating expense savings of approximately $10.0 million beginning in the first quarter of 2025. The charges Fulcrum expects to incur in connection with this reduction in force are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. Fulcrum may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.

Forward-Looking Statements

Forward-Looking Statements This current report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this report are forward-looking statements, including statements regarding the strategic operational realignment, estimated cost savings, estimated charges, suspending losmapimod development; redeployment of resources; further advancement of pociredir and Fulcrum's earlier stage program for DBA and other discovery programs; among others. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum's ability to realize the cost savings from the realignment; advance any earlier stage product candidates in or into clinical trials; initiating and enrolling clinical trials on the timeline expected or at all; replicating in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials; obtaining, maintaining or protecting intellectual property rights related to any product candidates; obtaining and maintaining necessary approvals from the FDA and other regulatory authorities; managing expenses; managing executive and employee turnover; and raising the substantial additional capital needed to achieve its busin

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date: September 24, 2024 By: /s/ Alex C. Sapir Name: Alex C. Sapir Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR